The latest market price of ceritinib/ceritinib in 2025

Ceritinib is a targeted drug targeting ALK (anaplastic lymphoma kinase) gene rearrangement. It is mainly used to treat patients with ALK-positive metastatic non-small cell lung cancer (NSCLC). Non-small cell lung cancer is the most common type of lung cancer. ALK gene rearrangement can cause tumor growth and spread in some patients. Therefore, the development of ceritinib aims to provide an effective treatment option for these patients.

Ceritinib prevents the growth and spread of cancer cells by specifically inhibiting the activity ofALK protein. Clinical studies have shown that ceritinib has good efficacy in patients with ALK-positive NSCLC, especially in patients who have failed first-line chemotherapy or other ALK inhibitor treatments. Because it is highly targeted and has relatively minor side effects, many patients are able to maintain a good quality of life after receiving treatment.

In China, ceritinib has been approved for marketing and included in the medical insurance directory, which greatly facilitates patients' access to the drug. Patients can purchase this drug in hospitals or pharmacies. The common packaging specifications are 150 mg and 150 pills (ie, 350 pills). Currently, the domestic market price is approximately between RMB 5,000 and RMB 10,000, and the specific price may vary depending on the region and sales channel.

In addition, ceritinib also has original drugs and generic drugs available in the international market. As the original manufacturer of ceritinib, the price of 150 mg of Novartis in Switzerland is generally more than RMB 10,000. The specific price is greatly affected by exchange rate changes. In overseas markets, especially in some developing countries, there are multiple generic drug options. For example, the specifications of generic drugs produced in Laos are 150 mg and 60 tablets, and the price is about more than 1,000 yuan. Although the price is more competitive, ensuring drug quality is still an important factor that patients need to pay attention to.

Reference materials:https://www.novartis.com/our-products/pipeline/ceritinib